This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Novartis expresses regret over South Korea kickbacks fine

( March 2, 2017, 12:44 GMT | Official Statement) -- MLex Summary: Swiss pharma company Novartis says it is committed to improving compliance procedures after its South Korean arm, Novartis Korea, was hit with a $200,000 fine by South Korea's drug standards agency. This follows allegations that it improperly paid doctors to recommend the company's medicines. The company, which faces similar allegations in other countries, has also been temporarily banned from selling some of its drugs in South Korea as part of the punishment.  The full Novartis statement follows....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections